Pathogenesis of osseous lesions in thalassemia

Choremis, C.; Liakakos, D; Tseghi, Christina; C, Moschovakis

doi:10.1016/s0022-3476(65)80072-5

Cited by 21 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However it is reported that iron overload leads to osteoblast poisoning (24) leading to false results for ALP and probably for osteocalcin. Low circulating ALP levels for the degree of osteopenia have also been reported by other researchers (25).…”

Section: Discussionsupporting

confidence: 81%

“…maintenance therapy, nutritional status and sun exposure, and in the range of metabolites which were determined. The aim of this study was to determine the serum levels of the three main metabolites of vitamin D, 25-hydroxyvitamin D (25-OHD), 24,25dihydroxyvitamin D (24,,D) and 1,2S-dihydroxyvitamin D (1 ,2D), together with other biochemical indices related to bone metabolism in thalassaemic patients aged between 5 and 23 years, in the summer and winter when the vitamin status differs.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D metabolites (25‐hydroxyvitamin D, 24,25‐dihydroxyvitamin D and 1,25‐dihydroxyvitamin D) and osteocalcin in β‐thalassaemia

et al. 1997

View full text Add to dashboard Cite

Serum levels of the vitamin D metabolites 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D, and of osteocalcin, C-terminal parathyroid hormone and other biochemical indices related to bone metabolism, were determined in two groups of patients with beta-thalassaemia aged 5-10 years (summer 7.8 +/- 0.4 years, mean +/- SEM, and winter 7.7 +/- 0.4 years, group A, n = 15) and 11-23 years (16.6 +/- 0.9 and 15.7 +/- 0.9 years in summer and winter, respectively, group B, n = 22). Emphasis was given to populations of school and adolescent ages and to the seasons of summer and winter when vitamin D status demonstrates the widest extremes. The mean serum levels of 25-hydroxyvitamin D in patients aged 5-10 years did not differ from those of controls during both seasons studied. In contrast, in the age group 11-23 years these levels were found to be lower in patients than in controls both in winter (10.6 +/- 0.9 ng/ml vs 15.0 +/- 2.0 ng/ml, p < 0.05) and summer (20.2 +/- 2.1 ng/ml vs 27.1 +/- 2.0 ng/ml, p < 0.05). The serum concentrations of 24,25-dihydroxyvitamin D were lower in the thalassaemic patients than in controls in both age groups and both seasons. In the patients under 10 years of age the mean values of this metabolite in winter were 1.06 +/- 0.17 ng/ml vs 1.68 +/- 0.20 ng/ml in the respective controls (p < 0.05), and in summer 1.44 +/- 0.11 ng/ml vs 2.35 +/- 0.36 ng/ml in controls (p < 0.05). In the group of patients aged 11-23 years, the mean levels of 24,25-dihydroxyvitamin D were in winter 0.65 +/- 0.12 ng/ml vs 1.12 +/- 0.19 ng/ml (p < 0.05) in controls and in summer 1.34 +/- 0.12 ng/ml vs 1.84 +/- 0.20 ng/ml (p < 0.05). The 1,25-dihydroxyvitamin D concentrations in both thalassaemic patient groups were significantly no different from those in the respective control groups. Serum osteocalcin, C-terminal parathyroid hormone, calcium, inorganic phosphate and alkaline phosphatase levels in the patients studied were not significantly different from those in controls, except for calcium and phosphate in the older group. In the older group of thalassaemic patients, serum calcium was lower than in the controls (2.26 +/- 0.03 vs 2.37 +/- 0.03 mmol/l, p < 0.05) in summer and serum phosphate higher than in the controls in winter (1.47 +/- 0.05 mmol/l vs 1.27 +/- 0.06 mmol/l, p < 0.05).

show abstract

Section: Discussionsupporting

confidence: 81%

mentioning

confidence: 99%

Vitamin D metabolites (25‐hydroxyvitamin D, 24,25‐dihydroxyvitamin D and 1,25‐dihydroxyvitamin D) and osteocalcin in β‐thalassaemia

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Bone changes are typical of thalassaemia major [5,9,12], but their pathogenesis remains a controversial question [6,8].…”

Section: Introductionmentioning

confidence: 99%

“…Although peroxisomes initially were regarded as having only a modest function in cellular metabolism, recent studies have indicated that peroxisomes are involved in a number of metabolic processes, including ether phospholipid biosynthesis [4,6], very long chain fatty acid oxidation [10], bile acid synthesis [7] and dicarboxylic acid oxidation [9]. Indeed the absence of peroxisomes in Zellweger syndrome is generally held responsible for the multitude of biochemical abnormalities, such as an accumulation of very long chain fatty acids [1], pipecolic acid [2] and trihydroxycoprostanoic acid [5].…”

Section: Introductionmentioning

confidence: 99%

Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major

Zamboni¹,

Marradi²,

Tagliaro³

et al. 1986

Eur J Pediatr

View full text Add to dashboard Cite

Serum calcium (Ca), phosphorus (P), alkaline phosphatase (Al-P), parathyroid hormone (PTH), calcitonin (CT), 25-hydroxyvitamin D3 (25OHD3), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) levels and urinary excretion of Ca, P, hydroxyproline (OH-P) and cyclic AMP (cAMP) were determined in summer and in winter in 13 thalassaemic children (7 aged 3-5 years-group 1-; and 6 aged 10-13 years-group 2-), who had never taken vitamin D supplements or therapy, and in two groups of 14 controls of the same age. In thalassaemics of group 1 only serum Al-P levels and OH-P urinary excretion were higher than in controls (P less than 0.01). In thalassaemics of group 2 Ca (P less than 0.05), P (P less than 0.05), PTH (P less than 0.001), CT (P less than 0.001), 25OHD3 (P less than 0.05), 1,25(OH)2D3 (P less than 0.001) levels and cAMP urinary excretion (P less than 0.001) were lower, whereas Al-P (P less than 0.001) and CT (P less than 0.001) levels and urinary excretion of P (P less than 0.05) and of OH-P (P less than 0.001) were higher than in controls, both in summer and in winter. Advancing age induces in thalassaemic patients a decrease in PTH secretion and a consequent deficit in synthesis of 1,25(OH)2D3 that may explain some aspects of bone changes, which CT hypersecretion may tend to counteract.

show abstract

“…CT treatment had no adverse effects on serum calcium and phosphorus levels or on liver tests and renal func tions, although a decrease in urine HOP levels has been reported in other studies [9-11, 13, 14], Hypocalcemia, hyperphosphatemia and high AP levels are due to disorders of PTH and 1.25 (OH)2 D3 metabo lisms in thalassemic patients with osteoporosis [1,3,7], AP levels increased significantly in the treatment-naive group, probably because of increased osteoporosis in this group.…”

Section: Discussionmentioning

confidence: 76%

Effects of Calcitonin Therapy on Osteoporosis in Patients with Thalassemia

Canatan

Akar

Arcasoy³

1995

Acta Haematol

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of calcitonin (CT) treatment on bone pain, osteoporosis, bone fractures and blood chemistry in thalassemic patients. Twenty-four patients with an age range of 10-24 years were included, 14 of whom received 100IU CT and 250 mg calcium 3 times a week. The others (n = 10) were followed up as a control group with only routine thalassemia therapy. After 1 year of treatment, bone pain disappeared and radiological signs of osteoporosis had improved significantly (p < 0.01) in the treatment group. CT has no important side effects.

show abstract

Pathogenesis of osseous lesions in thalassemia

Cited by 21 publications

References 2 publications

Vitamin D metabolites (25‐hydroxyvitamin D, 24,25‐dihydroxyvitamin D and 1,25‐dihydroxyvitamin D) and osteocalcin in β‐thalassaemia

Vitamin D metabolites (25‐hydroxyvitamin D, 24,25‐dihydroxyvitamin D and 1,25‐dihydroxyvitamin D) and osteocalcin in β‐thalassaemia

Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major

Effects of Calcitonin Therapy on Osteoporosis in Patients with Thalassemia

Contact Info

Product

Resources

About